Preview Mode Links will not work in preview mode

Jan 26, 2023

Featuring an interview with Professor Giuseppe Curigliano, including the following topics:

  • Vision for treating and curing HER2-positive metastatic breast cancer (mBC) in the future (0:00)
  • Optimal treatment of HER2-positive mBC with brain metastases (7:42)
  • Screening for and management of T-DXd-related interstitial lung disease (17:32)
  • Gastric toxicities associated with the tucatinib/trastuzumab/capecitabine regimen and with T-DXd; differences in the toxicity profiles of these therapies between patients with HER2-positive and HER2-low breast cancer (23:50)
  • Approach to endocrine therapy for triple-positive disease; emerging data with the AKT inhibitor capivasertib (28:43)
  • Case: A woman in her mid 40s with a family history of breast cancer and upper limb soft tissue sarcoma who presents with a right breast lump and axillary adenopathy on self-examination (35:44)

CME information and select publications